Results 181 to 190 of about 42,587 (212)

Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles. [PDF]

Cancer Res Commun
Poei D, Ali S, Thomas JS, Nieva JJ, Hsu RC.   +4 more
europepmc   +1 more source

Superficial Anaplastic Lymphoma Kinase-Rearranged Myxoid Spindle Cell Neoplasm in the Buttock: A Case Report. [PDF]

J Pers Med
Kim JH, Koh IC, Kim H, Lim SY, Choi JH, Kwon KY.   +5 more
europepmc   +1 more source

Cytomorphological and histomorphological features of lung adenocarcinoma with epidermal growth factor receptor mutation and anaplastic lymphoma kinase gene rearrangement. [PDF]

Oncol Lett
Gardić N, Lovrenski A, Sekeruš V, Kašiković Lečić S, Bijelović M, Lakić T, Ilić A, Zarić B, Glumac S.   +8 more
europepmc   +1 more source

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies. [PDF]

Biomedicines
Malighetti F, Villa M, Mauri M, Piane S, Crippa V, Crespiatico I, Cocito F, Bossi E, Steidl C, Civettini I, Scollo C, Ramazzotti D, Gambacorti-Passerini C, Piazza R, Mologni L, Aroldi A.   +15 more
europepmc   +1 more source

Bilateral breast metastases from anaplastic lymphoma kinase-positive lung cancer in a male: a case report. [PDF]

J Med Case Rep
Koh S, Koi Y, Tajiri W, Kawasaki J, Akiyoshi S, Nakamura Y, Koga C, Okamoto T, Taguchi K, Tokunaga E.   +9 more
europepmc   +1 more source

Combined BRAF G469A mutation and echinoderm microtubule associated protein like-4-anaplastic lymphoma kinase rearrangement with resistance: A case report and review of literature. [PDF]

World J Clin Oncol
Guo X, Liu Y, Wang YT, Liu K, Ding H.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anaplastic lymphoma kinase inhibitors

Current Opinion in Pharmacology, 2015
The anaplastic lymphoma kinase (ALK) gene is a member of the insulin receptor superfamily and it has been associated with more than twenty distinct chimera, including established drivers of several human cancers. Multiple clinical trials have proven that the pharmacological inhibition of ALK signaling leads to remarkable clinical improvement and ...
Ramona, Crescenzo, Giorgio, Inghirami
openaire   +2 more sources

Differential gene expression in anaplastic lymphoma kinase–positive and anaplastic lymphoma kinase–negative anaplastic large cell lymphomas

Human Pathology, 2005
Anaplastic large cell lymphoma (ALCL) is an aggressive large T- or null-cell lymphoma. Most ALCLs arising in children and young adults express a constitutively active receptor tyrosine kinase, anaplastic lymphoma kinase (ALK). Anaplastic large cell lymphomas lacking ALK are clinically heterogeneous and their pathogenesis is unknown.
Mary Ann, Thompson, Jennifer, Stumph, Sarah E, Henrickson, Andreas, Rosenwald, Qifu, Wang, Sandy, Olson, Stephen J, Brandt, Jeremy, Roberts, Xueqiong, Zhang, Yu, Shyr, Marsha C, Kinney   +10 more
openaire   +2 more sources

Anaplastic Lymphoma Kinase

2019
Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase, which is a member of the insulin receptor superfamily. Fusions in ALK result in constitutively activated signaling which is susceptible to inhibition by ALK tyrosine kinase inhibitors (TKIs). In this chapter we are describing management of patients with ALK-fused lung cancer.
Nicolas A. Villanueva, Nicholas P. Giustini, Lyudmila A. Bazhenova   +2 more
openaire   +1 more source

Anaplastic Lymphoma Kinase

2015
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) having an extracellular, a single transmembrane, and an intracellular domain containing the tyrosine kinase activity. ALK belongs to the insulin receptor subfamily of RTKs, most closely related to leukocyte tyrosine kinase receptor. It localizes mostly in neuronal cells and may play a
openaire   +2 more sources